miR-374 family is a key regulator of chronic primary pain onset.

IF 3.1 Q2 NEUROSCIENCES
Pain Reports Pub Date : 2024-10-16 eCollection Date: 2024-12-01 DOI:10.1097/PR9.0000000000001199
Nathaniel P Hernandez, Ashleigh Rawls, Jiegen Chen, Xin Zhang, Yaomin Wang, Xianglong Gao, Marc Parisien, Mohamad Karaky, Carolina Beraldo Meloto, Francesca Montagna, Hong Dang, Yue Pan, Ying Zhao, Samuel McLean, Sarah Linnstaedt, Luda Diatchenko, Andrea G Nackley
{"title":"miR-374 family is a key regulator of chronic primary pain onset.","authors":"Nathaniel P Hernandez, Ashleigh Rawls, Jiegen Chen, Xin Zhang, Yaomin Wang, Xianglong Gao, Marc Parisien, Mohamad Karaky, Carolina Beraldo Meloto, Francesca Montagna, Hong Dang, Yue Pan, Ying Zhao, Samuel McLean, Sarah Linnstaedt, Luda Diatchenko, Andrea G Nackley","doi":"10.1097/PR9.0000000000001199","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Chronic primary pain conditions (CPPCs) are linked to catecholamine activation of peripheral adrenergic receptors. Yet, catecholamine-dependent epigenetic mechanisms, such as microRNA (miRNA) regulation of mRNA transcripts, remain largely unknown.</p><p><strong>Objectives: </strong>We sought to identify RNA species correlated with case status in 3 pain cohorts, to validate RNAs found to be dysregulated in a mouse model of CPPC onset, and to directly test the role of adrenergic receptors in miRNA regulation. Furthermore, we tested antinociceptive effects of miR-374 overexpression.</p><p><strong>Methods: </strong>We used RNA-seq and quantitative reverse transcription polymerase chain reaction to measure RNA expression in 3 pain cohorts. Next, we validated identified RNAs with quantitative reverse transcription polymerase chain reaction in a mouse model of CPPC onset, measuring expression in plasma, peripheral (adipose, muscle, dorsal root ganglia [DRG]), and central (spinal cord) tissues. Then, we stimulated adrenergic receptors in primary adipocyte and DRG cultures to directly test regulation of microRNAs by adrenergic signaling. Furthermore, we used in vitro calcium imaging to measure the antinociceptive effects of miR-374 overexpression.</p><p><strong>Results: </strong>We found that one miRNA family, miR-374, was downregulated in the plasma of individuals with temporomandibular disorder, fibromyalgia syndrome, or widespread pain following a motor vehicle collision. miR-374 was also downregulated in plasma, white adipose tissue, and spinal cord from mice with multisite mechanical sensitivity. miR-374 downregulation in plasma and spinal cord was female specific. Norepinephrine stimulation of primary adipocytes, but not DRG, led to decreased miR-374 expression. Furthermore, we identified tissue-specific and sex-specific changes in the expression of predicted miR-374 mRNA targets, including known (HIF1A, NUMB, TGFBR2) and new (ATXN7, CRK-II) pain targets. Finally, we demonstrated that miR-374 overexpression in DRG neurons reduced capsaicin-induced nociceptor activity.</p><p><strong>Conclusions: </strong>Downregulation of miR-374 occurs between adrenergic receptor activation and mechanical hypersensitivity, and its adipocyte source implicates adipose signaling in nociception. Further study of miR-374 may inform therapeutic strategies for the millions worldwide who experience CPPCs.</p>","PeriodicalId":52189,"journal":{"name":"Pain Reports","volume":"9 6","pages":"e1199"},"PeriodicalIF":3.1000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11487220/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pain Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/PR9.0000000000001199","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Chronic primary pain conditions (CPPCs) are linked to catecholamine activation of peripheral adrenergic receptors. Yet, catecholamine-dependent epigenetic mechanisms, such as microRNA (miRNA) regulation of mRNA transcripts, remain largely unknown.

Objectives: We sought to identify RNA species correlated with case status in 3 pain cohorts, to validate RNAs found to be dysregulated in a mouse model of CPPC onset, and to directly test the role of adrenergic receptors in miRNA regulation. Furthermore, we tested antinociceptive effects of miR-374 overexpression.

Methods: We used RNA-seq and quantitative reverse transcription polymerase chain reaction to measure RNA expression in 3 pain cohorts. Next, we validated identified RNAs with quantitative reverse transcription polymerase chain reaction in a mouse model of CPPC onset, measuring expression in plasma, peripheral (adipose, muscle, dorsal root ganglia [DRG]), and central (spinal cord) tissues. Then, we stimulated adrenergic receptors in primary adipocyte and DRG cultures to directly test regulation of microRNAs by adrenergic signaling. Furthermore, we used in vitro calcium imaging to measure the antinociceptive effects of miR-374 overexpression.

Results: We found that one miRNA family, miR-374, was downregulated in the plasma of individuals with temporomandibular disorder, fibromyalgia syndrome, or widespread pain following a motor vehicle collision. miR-374 was also downregulated in plasma, white adipose tissue, and spinal cord from mice with multisite mechanical sensitivity. miR-374 downregulation in plasma and spinal cord was female specific. Norepinephrine stimulation of primary adipocytes, but not DRG, led to decreased miR-374 expression. Furthermore, we identified tissue-specific and sex-specific changes in the expression of predicted miR-374 mRNA targets, including known (HIF1A, NUMB, TGFBR2) and new (ATXN7, CRK-II) pain targets. Finally, we demonstrated that miR-374 overexpression in DRG neurons reduced capsaicin-induced nociceptor activity.

Conclusions: Downregulation of miR-374 occurs between adrenergic receptor activation and mechanical hypersensitivity, and its adipocyte source implicates adipose signaling in nociception. Further study of miR-374 may inform therapeutic strategies for the millions worldwide who experience CPPCs.

Abstract Image

Abstract Image

Abstract Image

miR-374 家族是慢性原发性疼痛发病的关键调节因子。
简介慢性原发性疼痛(CPPCs)与儿茶酚胺激活外周肾上腺素能受体有关。然而,儿茶酚胺依赖的表观遗传机制,如mRNA转录本的微RNA(miRNA)调控,在很大程度上仍不为人所知:我们试图在 3 个疼痛队列中鉴定与病例状态相关的 RNA 种类,验证在 CPPC 发病小鼠模型中发现的调控失调的 RNA,并直接测试肾上腺素能受体在 miRNA 调控中的作用。此外,我们还测试了 miR-374 过表达的抗痛觉效应:我们使用 RNA-seq 和定量反转录聚合酶链反应测量了 3 个疼痛队列中的 RNA 表达。接下来,我们在小鼠 CPPC 发病模型中用定量反转录聚合酶链反应验证了已确定的 RNA,测量了血浆、外周(脂肪、肌肉、背根神经节 [DRG])和中枢(脊髓)组织中的表达。然后,我们刺激了原代脂肪细胞和 DRG 培养物中的肾上腺素能受体,以直接测试肾上腺素能信号对 microRNA 的调控。此外,我们还利用体外钙成像技术测量了 miR-374 过表达的抗痛觉效应:我们发现,在颞下颌关节紊乱、纤维肌痛综合征或机动车碰撞后广泛性疼痛患者的血浆中,一个 miRNA 家族 miR-374 下调了。去甲肾上腺素刺激原发性脂肪细胞会导致 miR-374 表达下降,而 DRG 则不会。此外,我们还发现了预测的 miR-374 mRNA 靶点(包括已知的(HIF1A、NUMB、TGFBR2)和新的(ATXN7、CRK-II)疼痛靶点)表达的组织特异性和性别特异性变化。最后,我们证明了在DRG神经元中过表达miR-374能降低辣椒素诱导的痛觉感受器活性:结论:miR-374 的下调发生在肾上腺素能受体激活和机械超敏之间,其脂肪细胞来源与痛觉中的脂肪信号转导有关。对 miR-374 的进一步研究可能会为全球数百万经历过 CPPCs 的人提供治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pain Reports
Pain Reports Medicine-Anesthesiology and Pain Medicine
CiteScore
7.50
自引率
2.10%
发文量
93
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信